Sam L. Teichman

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA.

Corthera, Inc. develops and manufactures pharmaceuticals, such as cardiovascular preparations. It engages in acquiring, developing, and commercializing therapies for illnesses in the acute care setting. The company was founded in 2003 and is headquartered in San Carlos, CA.

Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA.

American College of Physicians, Inc. operates as a medical-specialty organization. It is a national organization of internists and physician specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and care of adults from health to complex illness. Its members include internists, internal medicine subspecialists, medical students, residents, and fellows. The company was founded in 1915 and is headquartered Philadelphia, PA.

American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC.

BEAT BioTherapeutics Corp. develops novel therapies for heart diseases. It offers BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. The company was founded by Charles E. Murry, Buddy D. Ratner, Michael Laflamme and Michael Regnier in 2008 and is headquartered in Bellevue, WA.